3SBIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.59 HKD | -0.90% |
|
0.00% | -12.37% |
| Apr. 22 | 3Sbio Inc. Announces Management Changes | CI |
| Apr. 15 | 3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 22,926 | 15,136 | 13,359 | 17,878 | 16,394 | 14,533 | - | - |
| Enterprise Value (EV) 1 | 23,645 | 14,959 | 13,120 | 20,196 | 18,543 | 15,363 | 13,534 | 12,276 |
| P/E ratio | 23.8 x | 18 x | 8.54 x | 9.91 x | 11 x | 8.01 x | 7.28 x | 6.58 x |
| Yield | - | - | 3.78% | 1.24% | - | 3.57% | 4.16% | 3.38% |
| Capitalization / Revenue | 4.31 x | 2.71 x | 2.09 x | 2.61 x | 2.1 x | 1.68 x | 1.54 x | 1.41 x |
| EV / Revenue | 4.45 x | 2.68 x | 2.06 x | 2.94 x | 2.37 x | 1.77 x | 1.43 x | 1.19 x |
| EV / EBITDA | 11.8 x | 9.31 x | 5.99 x | 7.22 x | 6.7 x | 5.4 x | 4.38 x | 3.62 x |
| EV / FCF | 16.9 x | 33.1 x | 23.9 x | 15.9 x | - | 11.2 x | 7.12 x | 5.93 x |
| FCF Yield | 5.93% | 3.02% | 4.19% | 6.29% | - | 8.96% | 14% | 16.9% |
| Price to Book | 2.38 x | 1.41 x | 1.1 x | 1.36 x | - | 0.95 x | 0.86 x | 0.76 x |
| Nbr of stocks (in thousands) | 2,539,974 | 2,543,601 | 2,522,355 | 2,438,845 | 2,398,563 | 2,382,112 | - | - |
| Reference price 2 | 9.026 | 5.950 | 5.296 | 7.330 | 6.835 | 6.101 | 6.101 | 6.101 |
| Announcement Date | 3/30/20 | 3/30/21 | 3/28/22 | 3/21/23 | 3/20/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5,318 | 5,588 | 6,382 | 6,859 | 7,816 | 8,661 | 9,458 | 10,301 |
| EBITDA 1 | 2,005 | 1,606 | 2,190 | 2,796 | 2,768 | 2,846 | 3,088 | 3,393 |
| EBIT 1 | 1,652 | 1,503 | 1,642 | 1,658 | 1,915 | 2,503 | 2,723 | 3,006 |
| Operating Margin | 31.06% | 26.89% | 25.73% | 24.18% | 24.51% | 28.9% | 28.79% | 29.18% |
| Earnings before Tax (EBT) 1 | 1,223 | 979.1 | 1,869 | 2,274 | 1,978 | 2,377 | 2,613 | 2,841 |
| Net income 1 | 973.7 | 835.8 | 1,651 | 1,915 | 1,549 | 1,937 | 2,137 | 2,305 |
| Net margin | 18.31% | 14.96% | 25.87% | 27.92% | 19.82% | 22.37% | 22.59% | 22.37% |
| EPS 2 | 0.3800 | 0.3300 | 0.6200 | 0.7400 | 0.6200 | 0.7618 | 0.8376 | 0.9278 |
| Free Cash Flow 1 | 1,403 | 451.6 | 549.2 | 1,271 | - | 1,376 | 1,901 | 2,069 |
| FCF margin | 26.38% | 8.08% | 8.61% | 18.53% | - | 15.89% | 20.1% | 20.08% |
| FCF Conversion (EBITDA) | 69.96% | 28.12% | 25.08% | 45.44% | - | 48.35% | 61.57% | 60.97% |
| FCF Conversion (Net income) | 144.06% | 54.03% | 33.26% | 66.36% | - | 71.01% | 88.99% | 89.77% |
| Dividend per Share 2 | - | - | 0.2000 | 0.0912 | - | 0.2180 | 0.2540 | 0.2060 |
| Announcement Date | 3/30/20 | 3/30/21 | 3/28/22 | 3/21/23 | 3/20/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,675 | 2,695 | 2,892 | 3,110 | 3,275 | 3,091 | 3,768 | 3,784 | 4,032 | 4,352 | 4,631 | 4,498 | 5,254 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | 915.3 | 727 | 802.5 | 855.8 | 1,301 | 614.8 | 1,427 | 1,312 | 1,496 | 1,494 |
| Operating Margin | - | - | - | 29.43% | 22.2% | 25.96% | 22.71% | 34.38% | 15.25% | 32.8% | 28.32% | 33.25% | 28.43% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | 0.2500 | 0.2700 | 0.0600 | 0.3400 | 0.2800 | 0.3700 | 0.3700 | 0.3900 | 0.2300 | 0.4400 | 0.3900 | 0.4500 | 0.4400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 8/17/20 | 3/30/21 | 8/25/21 | 3/28/22 | 8/24/22 | 3/21/23 | 8/24/23 | 3/20/24 | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 719 | - | - | 2,318 | 2,148 | 830 | - | - |
| Net Cash position 1 | - | 177 | 239 | - | - | - | 999 | 2,257 |
| Leverage (Debt/EBITDA) | 0.3587 x | - | - | 0.8291 x | 0.776 x | 0.2918 x | - | - |
| Free Cash Flow 1 | 1,403 | 452 | 549 | 1,271 | - | 1,376 | 1,901 | 2,069 |
| ROE (net income / shareholders' equity) | 10.7% | 8.23% | 15.1% | 15.2% | 11.5% | 12.5% | 12.4% | 12.3% |
| ROA (Net income/ Total Assets) | 6.8% | 5.15% | 8.95% | 9.3% | 6.79% | 8.23% | 8.38% | 8.44% |
| Assets 1 | 14,324 | 16,244 | 18,445 | 20,601 | 22,817 | 23,531 | 25,509 | 27,318 |
| Book Value Per Share 2 | 3.800 | 4.220 | 4.810 | 5.400 | - | 6.400 | 7.110 | 8.010 |
| Cash Flow per Share 2 | 0.7400 | 0.4900 | 0.5700 | 0.8200 | - | 0.7700 | 1.170 | 1.080 |
| Capex 1 | 471 | 893 | 1,029 | 910 | - | 905 | 842 | 1,089 |
| Capex / Sales | 8.86% | 15.98% | 16.13% | 13.26% | - | 10.45% | 8.9% | 10.57% |
| Announcement Date | 3/30/20 | 3/30/21 | 3/28/22 | 3/21/23 | 3/20/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
6.101
CNY
Average target price
6.893
CNY
Spread / Average Target
+12.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.37% | 2.01B | |
| -1.26% | 89.46B | |
| +2.76% | 40.74B | |
| -12.32% | 33.03B | |
| +55.07% | 24.68B | |
| -17.39% | 15.12B | |
| -9.14% | 12.81B | |
| -10.48% | 11.79B | |
| -42.45% | 11.64B | |
| +7.49% | 8.9B |
- Stock Market
- Equities
- 1530 Stock
- Financials 3SBio Inc.
